OSE IMMUNOTHERAPEUTICS EUR0.20 revenue for the last year amounted to 2.23 M EUR, the most of which — 2.23 M EUR — came from its highest performing source at the moment, Research and Development on Pharmaceutical Products, the year earlier bringing 18.30 M EUR. The greatest contribution to the revenue figure was made by France — last year it brought OSE IMMUNOTHERAPEUTICS EUR0.20 2.23 M EUR, and the year before that — 18.30 M EUR.